

## Pharnext to Present at 4<sup>th</sup> International Neurotech Investing and Partnering Conference

Paris, France, 5:45pm, September 28, 2017 (CEST) – Pharnext SA (FR00111911287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the 4th International Neurotech Investing and Partnering Conference.

The presentation will take place as follows:

- **Date:** Wednesday, October 4<sup>th</sup>, 2017
- **Time:** 4:00pm CEST
- **Venue:** Wyss Center in Geneva, Switzerland

If you are interested in meeting the Pharnext management team during this event, please send an email to Anne Hennecke at [anne.hennecke@mc-services.eu](mailto:anne.hennecke@mc-services.eu).

### About Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer's disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR00111911287). For more information, visit [www.pharnext.com](http://www.pharnext.com)

### CONTACTS:

#### Pharnext

Xavier Paoli

Chief Commercial Officer

[contact@pharnext.com](mailto:contact@pharnext.com)

+33 (0)1 41 09 22 30

**Investor Relations (Europe)**

MC Services AG

Anne Hennecke

[anne.hennecke@mc-services.eu](mailto:anne.hennecke@mc-services.eu)

+49 211 529252 22

**Media Relations (Europe)**

ALIZE RP

Caroline Carmagnol

Margaux Pronost

[pharnext@alizerp.com](mailto:pharnext@alizerp.com)

+33 (0)1 44 54 36 64

**Investor Relations (U.S.)**

Stern Investor Relations, Inc.

Matthew Shinseki

[matthew@sternir.com](mailto:matthew@sternir.com)

+1 212 362 1200

**Media Relations (U.S.)**

RooneyPartners

Marion Janic

[mjanic@rooneyco.com](mailto:mjanic@rooneyco.com)

+1 212 223 4017

**Financial Communication (France)**

Actifin

Stéphane Ruiz

[sruiz@actifin.fr](mailto:sruiz@actifin.fr)

+33 (0)1 56 88 11 15